BrainsWay develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and globally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. Founded in 2003, the company is headquartered in Jerusalem, Israel.
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders. Its core offering is the Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology, which is used to treat a range of conditions including major depressive disorder, anxious and late-life depression, obsessive-compulsive disorder, smoking addiction, bipolar disorder, post-traumatic stress disorder, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. The company serves doctors, hospitals, and medical centers in the field of psychiatry, primarily in the United States and globally.
Where is BrainsWay listed and what currency does it trade in?
BrainsWay Ltd. is listed on the NasdaqGM exchange under the ticker symbol BWAY. The company trades in US dollars (USD), which is the currency used for its stock transactions. Being listed on a major US exchange provides liquidity and visibility to investors, and the use of USD facilitates trading for international investors.
What sector and industry does BrainsWay operate in?
BrainsWay operates in the Healthcare sector, specifically within the Medical Devices industry. As a medical device company, it focuses on developing and commercializing innovative neurostimulation technologies for therapeutic use. The company's products are classified as medical devices and are used in clinical settings to treat various mental health and neurological disorders.
Where is BrainsWay headquartered and what markets does it serve?
BrainsWay Ltd. is headquartered in Jerusalem, Israel. The company serves customers in the United States and globally, with its Deep TMS platform being used by doctors, hospitals, and medical centers worldwide. While its primary market is the US, the company's treatments are available internationally, addressing a broad range of mental health and neurological conditions.
How does BrainsWay generate revenue?
BrainsWay generates revenue by selling its Deep Transcranial Magnetic Stimulation (Deep TMS) systems and related services to healthcare providers. The company's platform is used to treat multiple mental health disorders, and it earns income from the sale of devices, as well as potentially from service contracts or consumables. Its customers include doctors, hospitals, and medical centers in the psychiatry field. The company was founded in 2003 and has built a portfolio of indications, which helps drive adoption and recurring revenue from existing customers.